Renal transplant Equity through Partnership And Structural Transformation (REPAST)
通过伙伴关系和结构转型实现肾移植公平 (REPAST)
基本信息
- 批准号:10743661
- 负责人:
- 金额:$ 85.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAdultAdvocateAppointmentAssessment toolBlack PopulationsBlack raceCaregiversChronic Kidney FailureClinicalClinical TrialsCluster randomized trialCollaborationsCommunitiesCommunity Health AidesCountryDataDevelopmentDialysis patientsDialysis procedureDisparityEducationEligibility DeterminationEnd stage renal failureEnrollmentEnsureEquityEvaluationFaceFosteringFutureHealthHealth systemHealthcare SystemsHemodialysisHispanicHispanic PopulationsIndividualInequityInterventionInterviewKidneyKidney FailureKidney TransplantationLabelLanguageLeadLinkLow incomeMediatingMedicalMedicineMental DepressionMental HealthOperative Surgical ProceduresPainPatient CarePatient-Focused OutcomesPatientsPersonsPoliciesPopulation HeterogeneityProcessProviderRaceRacial EquityRenal Replacement TherapyResearchResearch PersonnelResortResourcesSocial supportStandardizationStigmatizationStructural RacismStructureSymptomsSystemTestingTrainingTransplant RecipientsTransplantationTransportationWaiting ListsWorkcommunity engaged researchcompare effectivenessdesignethnic disparityexperiencefood insecurityimpressionimprovedinnovationinterestoptimal treatmentspatient navigatorprimary outcomeprogram disseminationprogramspsychosocialracial discriminationracial disparityracismrecruitsocialsocial determinantssocial health determinantssuccesstooltransplant centerstreatment as usual
项目摘要
Abstract
Kidney transplantation (KTx) is considered the preferred treatment for patients with end-stage kidney
disease. Despite recent changes to the kidney allocation Black and Hispanic individuals are less likely
to receive KTx, a multi-step process requiring patient referral, patient medical/surgical/psychosocial
evaluation, and patient waitlisting. As there are no standardized acceptable metrics for psychosocial
evaluations, each of steps is impacted by provider and patient bias and thwarted by social determinants
often overlooked and structural racism continues to drive of racial and ethnic disparities in KTx. We
have identified barriers and facilitators to evaluation and waitlisting for KTx, including provider bias, high
unmet social determinants of health and symptom burden in patients on hemodialysis. To address the
impact of structure racism on KTx, we now propose a multi-level intervention in full partnership with an
Executive Stakeholder Board and Workgroups comprised of patients, clinicians, caregivers, advocates,
and system leaders for dialysis organizations and transplant centers. This work will be built on 2
decades of community-engaged research and trials to improve health in diverse populations. We will
work with the Board to develop an intervention based on past work by our team and others,
supplemented by formative interview with patients, caregivers, and clinicians. To increase rates of
patients receiving KTx evaluation, patient navigators who have chronic kidney disease and waitlisted
for kidney transplant or are transplant recipients themselves will guide patients through the transplant
evaluation process. This will include conducting a social needs screen and addressing barriers
uncovered, including facilitating appointments to address unmet needs such as food insecurity and
transportation, control of symptoms and mental health challenges. To increase rates of waitlisting
among those evaluated, we will identify stigmatizing language from KTx providers; notes and provide
an anti-bias initiative including structural changes to evaluation and education for KTx nephrologists.
We will evaluate the impact of this multifactorial intervention in a clinical trial among 320 adults with an
eGFR <20ml/min/1.73m2 or on in-center hemodialysis with a primary outcome of transplant waitlisting.
Together, we will also develop a blueprint of how to conduct this work, so that it can be used nationally
to reduce inequities and inform policies, systems and practices. Our Board will serve as a durable
resource for future kidney equity work.
摘要
肾移植(KTx)被认为是终末期肾病患者的首选治疗方法
疾病尽管最近肾脏分配发生了变化,但黑人和西班牙裔个体不太可能
接受KTx,这是一个多步骤的过程,需要患者转诊,患者医疗/手术/心理社会
评估和患者等待名单。由于没有标准化的可接受的指标,
评估,每个步骤都受到提供者和患者偏见的影响,并受到社会决定因素的阻碍
经常被忽视和结构性的种族主义继续推动KTx的种族和族裔差异。我们
我已经确定了KTx评估和等待名单的障碍和促进因素,包括提供者偏见,高
血液透析患者健康和症状负担的未满足的社会决定因素。解决
结构性种族主义对KTx的影响,我们现在建议与
执行利益相关者委员会和工作组由患者、临床医生、护理人员、倡导者组成,
以及透析组织和移植中心的系统领导者。这项工作将建立在2
数十年的社区参与研究和试验,以改善不同人群的健康。我们将
与董事会合作,根据我们团队和其他人过去的工作制定干预措施,
辅以与患者、护理人员和临床医生的形成性访谈。为了提高
接受KTx评价的患者,患有慢性肾脏疾病和等待名单的患者导航员
对于肾移植或移植受者本身将指导患者通过移植
评估过程。这将包括进行社会需求筛查和消除障碍
未被发现的问题,包括促进任命,以解决粮食不安全等未得到满足的需求,
交通、症状控制和心理健康挑战。提高等待登记率
在接受评估的人中,我们将确定KTx提供者的侮辱性语言;注意并提供
一项反偏见倡议,包括对KTx肾科医生的评价和教育进行结构性改革。
我们将在一项临床试验中评估这种多因素干预对320名患有糖尿病的成人的影响。
eGFR <20 ml/min/1.73 m2或接受中心内血液透析,主要结局为移植等待。
我们还将共同制定如何开展这项工作的蓝图,以便在全国范围内使用
减少不公平现象,并为政策、制度和做法提供信息。我们的董事会将作为一个持久的
未来肾脏权益工作的资源。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lili Chan其他文献
Lili Chan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lili Chan', 18)}}的其他基金
Improving risk prediction of adverse outcomes in hemodialysis patients by incorporating non-traditional risk factors
通过纳入非传统风险因素改善血液透析患者不良结果的风险预测
- 批准号:
10327321 - 财政年份:2021
- 资助金额:
$ 85.91万 - 项目类别:
Improving risk prediction of adverse outcomes in hemodialysis patients by incorporating non-traditional risk factors
通过纳入非传统风险因素改善血液透析患者不良结果的风险预测
- 批准号:
10530671 - 财政年份:2021
- 资助金额:
$ 85.91万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 85.91万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 85.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 85.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 85.91万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 85.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 85.91万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 85.91万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 85.91万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 85.91万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 85.91万 - 项目类别:
Standard Grant